[Back to Our Trials]

SET-101: A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Condition: Diffuse Large B-Cell Lymphoma, Multiple Myeloma


Go To Trial Homepage


For more information you may call clinical trials department directly at 732-390-7750 or email us at astera.clinicaltrial@asterahealthcare.org.